Certara Inc
CERT
Company Profile
Business description
Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval, and increase patient access to medicines. The company has its business presence in the Americas, which is also its key revenue-generating market, EMEA, and the Asia Pacific region.
Contact
4 Radnor Corporate Center
Suite 350
RadnorPA19087
USAT: +1 415 237-8272
Sector
Healthcare
Stock type
Defensive
Industry
Health Information Services
Fiscal Year End
31 December 2026
Employees
1,576
Stocks News & Analysis
stocks
Wide moat ASX share beats earnings guidance
Wide moat share continues to grow despite a challenging residential construction market.
stocks
Cheap with attractive yield: Fair Value lifted for retail REIT after earnings
Management expects both earnings and distributions to increase next year.
stocks
Cheap ASX share may have more room to run
Shares are cheap despite rebounding share price, yet risks remain.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,443.70 | 17.90 | 0.19% |
| CAC 40 | 8,714.94 | 11.09 | -0.13% |
| DAX 40 | 26,395.37 | 71.49 | 0.27% |
| Dow JONES (US) | 53,925.67 | 50.31 | -0.09% |
| FTSE 100 | 10,844.19 | 18.31 | -0.17% |
| HKSE | 25,652.82 | 284.67 | -1.10% |
| NASDAQ | 26,507.28 | 98.08 | -0.37% |
| Nikkei 225 | 66,970.22 | 1,363.51 | 2.08% |
| NZX 50 Index | 13,860.66 | 27.58 | -0.20% |
| S&P 500 | 7,742.05 | 11.06 | -0.14% |
| S&P/ASX 200 | 9,250.60 | 13.80 | 0.15% |
| SSE Composite Index | 3,934.09 | 32.50 | -0.82% |